Radiolabelling and Biological Assessment of 99mTc-Mebeverine as a Possible Tracer for Solid Tumor Diagnosis

Abstract

N UCLEAR medicine is one the most important fields to inspect and treat tumors by radiation or by introducing labeled radiopharmaceuticals, which are in the spot of our interest. In this study, the authors investigated the possibility of using mebeverine as a solid tumor marker. Mebeverine was labeled with Technetium ( 99m Tc-Meb) reaching a radiochemical yield (RCY) of 97% via a reduction reaction using SnCl 2 . The tracer showed a high stability in the serum for 12 hours which is essential to avoid any undesired accumulations in the non-target organs. Its bioevaluation in normal and induced tumored mice was performed to identify the capability of the use of the tracer for the diagnosis of solid tumors. The uptake by the tumor was 14.2% after 30 min of injection and increased to 18.5%, viewing a decline after 3 hours, this could be attributed to that washout to the tumored muscle extravasation. Tumored /Non-Tumored (T/ NT) ratio was applied, the ratio reached 3.14 which shows the selectivity of 99m Tc-Meb to the solid tumor induced in the right thigh.

Bioevaluation of 99mTc-Pipazethate as a potential guide tracer for malignant tumor imaging.

“…Using the Student's unpaired test, statistical differences were found to be reproducible when p<0.05 between normal and tumored muscle. Tumored (Left thigh) /Non Tumored (right thigh) ratio is an essential factor to estimate the selectivity and the sensitivity of any radiotracer to solid tumor [33][34].T/NT ratio reached 2.9 at 30 min post injection ,this high value showed that 99m Tc-Pip is a potential solid tumor indicator in comparision to 99m Tcnitridepyrazolol[1,5-a] pyrimidine (2.2 at 1h p.i) [36], 99m Tc-BnAO-NI (2.59, 2 h p.i.) [37] and 99m Tc-Meb (2.59 at 30min p.i) [ 34].…”